RetroSense Therapeutics, LLC
http://retrosense.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From RetroSense Therapeutics, LLC
Finance Watch: Mysterious Gossamer Raises $100m As VC Deals Surge Ahead of J.P. Morgan
Gossamer Bio, led by former Receptos CEO Faheem Hasnain and CMO Sheila Gujrathi, revealed $100m in seed and Series A funding during a week in which 17 companies revealed VC rounds totaling $891.2m, giving them good news to discuss during the J.P. Morgan Healthcare conference.
Horama's Gene Therapies For Retinal Diseases: Fast Followers?
French biotech Horama has built-up its executive team and has two potential gene therapies for retinitis pigmentosa nearing the clinic.
Biopharma Quarterly Dealmaking Statistics, Q3 2016
In Q3, biopharma financing totaled $7.4 billion, a large proportion of which was by rare disease developers; among the highlights in the $23 billion in M&As was Allergan's buying spree, including two NASH companies. Just over $20 billion went into biopharma alliance dealmaking, and neurology assets attracted many of the dollars.
‘Open Science’ In Action: Allergan Exercises Option For Motus After Gastroparesis Study
Allergan will pay $200m to exercise its option to buy Motus Therapeutics (formerly Rhythm Health) after what the pharma described as a successful Phase IIb study for relamorelin in diabetic gastroparesis.